Miragen Therapeutics, Inc.

Miragen Therapeutics, Inc.

Miragen Therapeutics, Inc.

Overview
Date Founded

2006

Headquarters

6200 Lookout Road, Boulder, CO, 80301, USA

Type of Company

Public

Employees (Worldwide)

80

Industries

Pharmaceuticals
Biotechnology

Company Description

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer

Chief Medical Officer

Co-Founder, Director

Board of Directors

Chief Executive Officer & Director at Zafgen, Inc.

Director, President & Chief Executive Officer at Miragen Therapeutics, Inc.

Distinguished Professor of Chemistry & Biochemistry at The University of Colorado

President & Chief Executive Officer at Navitor Pharmaceuticals, Inc.

Chief Executive Officer at Willow Advisors LLC

Chief Medical Officer at Agios Pharmaceuticals, Inc.

Venture Partner at OrbiMed Advisors LLC

Swarthmore College

Paths to Miragen Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Miragen Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Atlas Venture focuses on investments in early-stage companies operating in the fields of biotechnology. The firm partners with entrepreneurs to build companies around innovative science.

Details Hidden

Atlas Venture focuses on investments in early-stage companies operating in the fields of biotechnology. The firm partners with entrepreneurs to build companies around innovative science.

Recent Transactions
Details Hidden

Miragen Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Director

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Professional

Advised onMiragen Therapeutics, Inc. issued USD Common Stock

Clients

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Key Stats and Financials As of 2018
Market Capitalization
$24M
Total Enterprise Value
$37.5M
Earnings Per Share
$-1.1
TEVNet Income
-1.15x
Debt TEV
0.27x
Enterprise Value Sales
4.47x
Total Equity
$51.3M
Total Debt
$10.3M
EBITDAMargin
-391.16%
EBITDA
$-32.8M
Net Profit
$-32.7M
Revenue
$8.39M
Five Year Compounded Annual Growth Rate Of Revenue
14.2%
Three Year Compounded Annual Growth Rate Of Revenue
48.94%
Suppliers
Roche Holding AG Medical Support Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

The Brigham & Women's Hospital, Inc. Medical Support Services | Boston, MA

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $537 million in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative.

The University of Texas at Austin Power & Utilities | Austin, TX

The University of Texas at Austin is one of the largest public universities in the United States and is the largest institution of The University of Texas System. Founded in 1883, the university has grown from a single building, eight teachers, two departments and 221 students to a 350-acre main campus with 17 colleges and schools, about 24,000 faculty and staff, and more than 50,000 students.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Miragen Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Miragen Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Miragen Therapeutics, Inc..